DAX-0,59 % EUR/USD+0,22 % Gold+0,68 % Öl (Brent)-1,52 %

Titan Medical Annual and Special Meeting Scheduled for Wednesday, May 29, 2019

Nachrichtenquelle: Business Wire (engl.)
22.05.2019, 23:15  |  438   |   |   

Titan Medical Inc. (“Titan” or the “Company”) (TSX: TMD) (Nasdaq: TMDI), a medical device company focused on the design, development and commercialization of a robotic surgical system for application in single-port minimally invasive surgery (“MIS”), announces that its 2019 Annual and Special Meeting is scheduled for Wednesday, May 29, 2019 at 12:00 p.m. (Eastern), to be held at the Toronto Hilton Hotel, 145 Richmond Street West, Simcoe Room, Main Lobby.

Items to be presented and voted on at this year’s Annual and Special Meeting include the following:

  1. Presentation of the audited financial statements of the Corporation for the fiscal year ended December 31, 2018,
  2. the election of directors of the Corporation for the ensuing year;
  3. the appointment BDO Canada LLP as the auditor of the Corporation and authorization of the directors to fix the remuneration of the auditors;
  4. the adoption of a share unit plan and a deferred share unit plan of the Corporation and the reservation of common shares for issuance pursuant to each plan;
  5. increasing the Corporation’s stock option plan (the “Option Plan”) from a rolling 10% plan to a rolling 15% plan; and
  6. the amendment of the exercise prices of options granted to executive officers and other employees who are insiders of the Corporation under the Option Plan to the higher of the March 21, 2019 offering price of US$3.40 and the five day volume-weighted average price determined as of the close of business on May 28, 2019 (“Exercise Price Amendment”). As the Exercise Price Amendment constitutes a “related party transaction” as such term is defined in Multilateral Instrument 61-101. The Company intends to rely on the exemption from the “minority approval” requirement of MI 61-101 set forth in section 5.7(a) of MI 61 101, as the fair market value of the Exercise Price Amendment does not exceed 25% of the market capitalization of the Company. The expiry dates of the options subject to the Exercise Price Amendment are not being amended, and the range of option expiry dates are set forth in the management information circular dated April 29, 2019.

“We look forward to this year’s Annual and Special Meeting and encourage shareholders to attend the meeting and vote in person or to duly complete and deliver their proxies in advance of the meeting”, commented David McNally, Chief Executive Officer.

Seite 1 von 3

0 Kommentare

Schreibe Deinen Kommentar

Bitte melden Sie sich an, um zu kommentieren. Anmelden | Registrieren



Meistgelesene Nachrichten des Autors